Merck Heads into Q2 Earnings with Analysts Expecting 3% Revenue Growth

Merck (NYSE: MRK), a global pharmaceutical company, will announce its Q2 earnings results on Tuesday before market hours. In the previous quarter, Merck beat analysts' revenue expectations with $16.29 billion in revenues, a 4.9% year-on-year increase.

This quarter, analysts expect Merck's revenue to grow by 3%, a reversal from the 1.9% decrease recorded in the same period last year. Analysts covering the company have reconfirmed their estimates over the past 30 days, suggesting they anticipate the business will continue on its current trajectory.

Merck has a strong track record of meeting Wall Street's revenue expectations, with some peers already reporting their Q2 results. Corcept delivered year-on-year revenue growth of 7.3%, while Bristol-Myers Squibb reported revenues up 5.7%. Both companies' share prices have seen significant increases following their results.